Evidence map›Paper›PMID 33486722›Full record

ArticleHuman cell2021

Targeted deletion of HAI-1 increases prostasin proteolysis but decreases matriptase proteolysis in human keratinocytes.

Dajun D Lu, Yayun Gu, Sheng-Wen A Li, Robert J Barndt, Shih-Ming Huang, Jehng-Kang Wang, Hui Chen Su, Michael D Johnson, Chen-Yong Lin

Abstract read
PubMed Publisher
In one paragraph

Article in Human cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Dajun D LuLombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, W412 Research Building 3970 Reservoir Road NW, Washington, DC, 20057, USA.
Yayun GuLombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, W412 Research Building 3970 Reservoir Road NW, Washington, DC, 20057, USA.
Sheng-Wen A LiSchool of Medicine, National Defense Medical Center, Taipei 114, Taiwan.
Robert J BarndtLombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, W412 Research Building 3970 Reservoir Road NW, Washington, DC, 20057, USA.
Shih-Ming HuangDepartment of Biochemistry, National Defense Medical Center, Taipei 114, Taiwan.
Jehng-Kang WangDepartment of Biochemistry, National Defense Medical Center, Taipei 114, Taiwan.
Hui Chen SuDepartment of Pharmacy, Chi-Mei Medical Center, Tainan, Taiwan. Michael.maggil@gmail.com.
Michael D JohnsonLombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, W412 Research Building 3970 Reservoir Road NW, Washington, DC, 20057, USA. johnsom@georgetown.edu.
Chen-Yong LinLombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, W412 Research Building 3970 Reservoir Road NW, Washington, DC, 20057, USA. lincy@georgetown.edu.ORCID http://orcid.org/0000-0002-6391-2571
Georgetown University · USNational Defense Medical Center · TWChi Mei Medical Center · TW

Funding

Mechanisms of Deregulation of Matriptase in Breast CancerR01CA123223 · NCI · GEORGETOWN UNIVERSITY · PI JOHNSON, MICHAEL D, LIN, CHEN-YONG · 2010 to 2014
$1.6M
Chi Mei Medical Center (TW) CMNDMC10703Chi Mei Medical Center (TW) CMNDMC10807Ministry of National Defense Medical Affairs Bureau, Taiwan MAB-108-079NCI NIH HHS CA 123223
6 · The paper itself

Abstract

Epidermal differentiation and barrier function require well-controlled matriptase and prostasin proteolysis, in which the Kunitz-type serine protease inhibitor HAI-1 represents the primary enzymatic inhibitor for both proteases. HAI-1, however, also functions as a chaperone-like protein necessary for normal matriptase synthesis and intracellular trafficking. Furthermore, other protease inhibitors, such as antithrombin and HAI-2, can also inhibit matriptase and prostasin in solution or in keratinocytes. It remains unclear, therefore, whether aberrant increases in matriptase and prostasin enzymatic activity would be the consequence of targeted deletion of HAI-1 and so subsequently contribute to the epidermal defects observed in HAI-1 knockout mice. The impact of HAI-1 deficiency on matriptase and prostasin proteolysis was, here, investigated in HaCaT human keratinocytes. Our results show that HAI-1 deficiency causes an increase in prostasin proteolysis via increased protein expression and zymogen activation. It remains unclear, however, whether HAI-1 deficiency increases "net" prostasin enzymatic activity because all of the activated prostasin was detected in complexes with HAI-2, suggesting that prostasin enzymatic activity is still under tight control in HAI-1-deficient keratinocytes. Matriptase proteolysis is, however, unexpectedly suppressed by HAI-1 deficiency, as manifested by decreases in zymogen activation, shedding of active matriptase, and matriptase-dependent prostasin zymogen activation. This suppressed proteolysis results mainly from the reduced ability of HAI-1-deficient HaCaT cells to activate matriptase and the rapid inhibition of nascent active matriptase by HAI-2 and other yet-to-be-identified protease inhibitors. Our study provides novel insights with opposite impacts by HAI-1 deficiency on matriptase versus prostasin proteolysis in keratinocytes.

Indexed as

Gene DeletionProteolysisHaCaT CellsHumansKeratinocytesProstasinProteinase Inhibitory Proteins, SecretorySerine EndopeptidasesSkinmatriptaseProstasinProteinase Inhibitory Proteins, SecretorySerine EndopeptidasesSPINT1 protein, humanHAI-1MatriptaseProstasinProteolysisSkin

Identifiers

PMID33486722
OpenAlexW3123466888

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.